Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CHS-1701 · Armlupeg, Neulasta

Recombinant protein · Agonist of granulocyte colony-stimulating factor receptor (CSF3R) · developed by Amgen

Approved FDA, Jan 2002
1 Registered trials

What is CHS-1701?

CHS-1701 is a pegfilgrastim product, a colony-stimulating factor that binds cell surface receptors on hematopoietic cells to stimulate their proliferation, differentiation and functional activation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Armlupeg, Neulasta, Nyvepria, Ziextenzo
Drug type
Recombinant protein
Targets
granulocyte colony-stimulating factor receptor (CSF3R)
Mechanism
Agonist of granulocyte colony-stimulating factor receptor (CSF3R)
Pathways
hematopoietic cell proliferation, hematopoietic cell differentiation
Therapy area
Hematology, Oncology
Developer
Amgen
In trials of
CHRS
FDA status
Approved as Armlupeg, Neulasta, Nyvepria (January 31, 2002), BLA125031 · FDA label

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02650973 Phase 1 Healthy Completed CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.